MedVector
Transforming Clinical Trials
Analytics
Raised to Date: $624,853
Aggregate Commitments $
StartEngine
10/27/2020
04/21/2021
$9,999
$1,070,000
$496
Equity - Common
RegCF
Pre-Seed
$10,000,000
Weekly Commitments $
Active
01/17/2021
92
6,249%
58%
$7,620
359
El Segundo, California
Healthcare & Pharmaceuticals
HealthTech
B2B
Medium
Low
MedVector, with a $10 million pre-money valuation, is raising crowdfunding on StartEngine. It is a telemedicine platform that aims to accelerate clinical trials. The platform will connect subjects from across the world to clinical trial sites and increase participation in clinical trials. Scott Stout and Dr. Dennis Patterson founded MedVector in 2017. The current crowdfunding round has a minimum target of $9,999.20 and a maximum target of $1,069,999.95, and the proceeds will be used for the launch of the platform. MedVector platform has access to seven hospitals consisting of hundreds of thousands of patients per year. The company has signed two LOIs and completed three case studies with Novartis.
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-512,457 |
$-311,702 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$26,998 |
$148,600 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$253,690 |
$188,600 |
|
Short-Term Debt |
$208,552 |
$500,302 |
|
Long-Term Debt |
$0 |
$0 |
|
Total Liabilities |
$208,552 |
$500,302 |
Ratings
Ratings Platform - Beta Trial
Our new ratings and analytics platform is currently in Beta. To gain access to the Beta platform features, upgrade to a Pro paid account and accept the Beta terms on any page.
For a limited time, use coupon code "TRYMERLIN20" for a free 20 day trial of Kingscrowd Pro and Merlin Beta. Your paid subscription will activate at the end of 20 days. Cancel anytime.Other Deals
Millennial Fertility Co. on NetCapital
The Millennial Fertility Co. team has been selected as a “Deal to Watch” by KingsCrowd. This distinction is…
Biopact on Equifund CFP
Biopact has been selected as a “Deal to Watch” by KingsCrowd. This distinction is reserved for deals selected…
Neurotez Inc. on NetCapital
Neurotez has been selected as a “Deal To Watch” by KingsCrowd. This distinction is reserved for deals selected…